| Keywords [eng] |
Preeclampsia outcomes, preeclampsia, preeclampsia microRNA, preeclampsia uterine pulsatile index, preeclampsia maternal outcomes, preeclampsia sFLT-1/PlGF ratio, preeclampsia maternal and fetal outcomes |
| Abstract [eng] |
This literature review has the purpose of studying relevant scientific papers on the topic of preeclampsia from the years of 2012 to 2022. The aim is to identify current diagnosis principles as well as newly suggested diagnoses and treatment methods during each year and compare the results to each other. Also, three preeclampsia complications have been researched for each year of the decade: placental abruption, “hemolysis, elevated liver enzymes, low platelets”- syndrome or parts of it and eclampsia or use of magnesium sulfate. Methodically, scientific papers were searched for with PubMed and Google Scholar with the keywords listed below and filtered by year. Either one or more papers were chosen for a specific year and the most relevant information for this literature review was filtered out. The results are that certain researched factors, such as soluble fms-like tyrosine kinase 1 to placental growth factor (sFlt-1/PlGF) ratio, were disagreed upon in terms of importance by different researchers throughout the years. More importantly, there are several findings that deserve to be expanded on further: including micro ribonucleic acids (microRNAs), estrogen, ceruloplasmin and the administration of 17-alpha-hydroxyprogesterone caproate (17-OHPC). As for maternal outcomes, the variation was quite high. No certain trends could be identified on an international scale. To conclude, preeclampsia, its pathogenesis, diagnosis, and treatment have not been researched appropriately in the last decade. For the safety of pregnant women and their fetuses, the recommendation of this literature review is to continue studying the disease and its aspects. |
